POLA1 and cancer: Also, Dallavalle et al. reported that a POLA1-HDAC1 dual inhibitor, MIR002, inhibits the primer extension activity of POLA1, resulting in antiproliferative effects on various human cancer cell lines, including ovarian cancer66.